SRC and neoplasm: Although we are unable to substantiate the in vitro studies suggesting a role for c-Src in tamoxifen resistance we feel that further clarification defining the role of c-Src in the different subtypes of breast cancer, particularly in ER-negative breast cancer and recurrent tumours, is warranted as this likely represents the group in which targeted Src Kinase inhibition may be beneficial to patient outcome.